These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15897589)

  • 1. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
    Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
    Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.
    Vallera DA; Todhunter D; Kuroki DW; Shu Y; Sicheneder A; Panoskaltsis-Mortari A; Vallera VD; Chen H
    Leuk Res; 2005 Mar; 29(3):331-41. PubMed ID: 15661270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
    Pop LM; Liu X; Ghetie V; Vitetta ES
    Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
    Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
    Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
    Chaouchi N; Vazquez A; Galanaud P; Leprince C
    J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
    Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
    Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.